-
Je něco špatně v tomto záznamu ?
Food industrial microbial transglutaminase in celiac disease: treat or trick
Aaron Lerner, Torsten Matthias
Jazyk angličtina Země Spojené státy americké
- Klíčová slova
- mikrobiální transglutaminázy, imunogenicita, tkáňové transglutaminázy, střevní propustnost,
- MeSH
- autoimunitní nemoci diagnóza MeSH
- celiakie * diagnóza dietoterapie imunologie prevence a kontrola terapie MeSH
- gluteny MeSH
- incidence MeSH
- lidé MeSH
- mouka normy škodlivé účinky MeSH
- potravinářský průmysl metody organizace a řízení trendy MeSH
- rizikové faktory MeSH
- Check Tag
- lidé MeSH
The surge in incidence of celiac disease (CD) is due more to environmental than to genetic changes. It is paralleled by a food industry that is continuously introducing additives to processed products. Microbial transglutaminase (mTG) is an enzyme that deamidates/transamidates proteins, enabling cross-linkage of molecules and revolutionizing the properties of many food products. It belongs to the family of transaminases and tissue transglutaminase (tTG) has been identified as the autoantigen in CD. Both enzymes de/transamidate gluten, the nutritional environmental factor that induces CD. Although several studies have shown that mTG transamidation of wheat flour/gluten can detoxify gluten peptide in vitro, by inhibiting the response to intestinal gliadin, inducing T cells and reducing INFγ production without influencing their main technological properties, a word of caution is advised. The oral challenge of adult CD patients with mTG transamidated flour was found to be only partially effective, not fulfilling expectations, and there have been multiple recent observations that indicate that mTG transamidated flour/gluten could be dangerous to gluten sensitive populations: mTG cross-linking of gluten may be hazardous in CD since the enzyme can deamidate gluten, thus mimicking endogenous tTG, it can link an extensive repertoire of proteins and other macromolecules with immunogenic potential, mTG treated gluten peptides are immunogenic to celiac patients, inducing specific IgA antibodiesand are recognized by gluten-specific humanT cells. Their effect on CD intestinal permeability has not yet been studied. To better understand the actual processes and events, associated with the suggested mTG therapy, long-term ex vivo and in vitro studies are needed. Until then, it is best to respect the data but suspect the safety of the gluten sensitive populations.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15025349
- 003
- CZ-PrNML
- 005
- 20151122143952.0
- 007
- ta
- 008
- 150727s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.12691/ijcd-3-1-10 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Lerner, Aaron $u Pediatric Gastroenterology and Nutrition Unit, Carmel Medical Center, B, Rappaport School of Medicine, Technion-Israel institute of Technology, Haifa, Israel
- 245 10
- $a Food industrial microbial transglutaminase in celiac disease: treat or trick / $c Aaron Lerner, Torsten Matthias
- 504 __
- $a Literatura
- 520 9_
- $a The surge in incidence of celiac disease (CD) is due more to environmental than to genetic changes. It is paralleled by a food industry that is continuously introducing additives to processed products. Microbial transglutaminase (mTG) is an enzyme that deamidates/transamidates proteins, enabling cross-linkage of molecules and revolutionizing the properties of many food products. It belongs to the family of transaminases and tissue transglutaminase (tTG) has been identified as the autoantigen in CD. Both enzymes de/transamidate gluten, the nutritional environmental factor that induces CD. Although several studies have shown that mTG transamidation of wheat flour/gluten can detoxify gluten peptide in vitro, by inhibiting the response to intestinal gliadin, inducing T cells and reducing INFγ production without influencing their main technological properties, a word of caution is advised. The oral challenge of adult CD patients with mTG transamidated flour was found to be only partially effective, not fulfilling expectations, and there have been multiple recent observations that indicate that mTG transamidated flour/gluten could be dangerous to gluten sensitive populations: mTG cross-linking of gluten may be hazardous in CD since the enzyme can deamidate gluten, thus mimicking endogenous tTG, it can link an extensive repertoire of proteins and other macromolecules with immunogenic potential, mTG treated gluten peptides are immunogenic to celiac patients, inducing specific IgA antibodiesand are recognized by gluten-specific humanT cells. Their effect on CD intestinal permeability has not yet been studied. To better understand the actual processes and events, associated with the suggested mTG therapy, long-term ex vivo and in vitro studies are needed. Until then, it is best to respect the data but suspect the safety of the gluten sensitive populations.
- 650 12
- $a celiakie $x diagnóza $x dietoterapie $x imunologie $x prevence a kontrola $x terapie $7 D002446
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a gluteny $7 D005983
- 650 _2
- $a potravinářský průmysl $x metody $x organizace a řízení $x trendy $7 D019649
- 650 _2
- $a mouka $x normy $x škodlivé účinky $7 D005433
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a autoimunitní nemoci $x diagnóza $7 D001327
- 650 _2
- $a lidé $7 D006801
- 653 10
- $a mikrobiální transglutaminázy
- 653 10
- $a imunogenicita
- 653 00
- $a tkáňové transglutaminázy
- 653 00
- $a střevní propustnost
- 700 1_
- $a Matthias, Torsten $u Aesku. Kipp Institute, Wendelsheim, Germany
- 773 0_
- $t International journal of celiac disease $x 2334-3427 $g Roč. 3, č. 1 (2015), s. 1-6 $w MED00186448
- 856 41
- $u http://www.sciepub.com/journal/index.aspx?id=ijcd $y domovská stránka časopisu
- 910 __
- $a ABA008 $b B 2748 $c 280 $y 4 $z 0
- 990 __
- $a 20150723102837 $b ABA008
- 991 __
- $a 20151122144019 $b ABA008
- 999 __
- $a ok $b bmc $g 1085556 $s 908355
- BAS __
- $a 3
- BMC __
- $a 2015 $b 3 $c 1 $d 1-6 $i 2334-3427 $m International journal of celiac disease $x MED00186448
- LZP __
- $c NLK185 $d 20151121 $a NLK 2015-19/mk